Finerenone
Treatment for Chronic Kidney Disease Due To Diabetes Mellitus Type 2
Typical Dosage: 10-20mg daily
Effectiveness
88%
Safety Score
65%
Clinical Trials
2
Participants
13K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Dosage Range
10-20mg daily
Time to Effect
6-12 months for sustained renal benefits
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
35(Treat 35 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
15(Treat 15 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$7,200
Monitoring:$1,700
Side Effect Mgmt:$300
Total Annual:$9,200
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$130,000/QALY
QALYs Gained
0.5
Outcome-Based Costs
Cost per Responder
$12,266.67
Comparison vs ACE inhibitor/ARB alone
Cost Difference
+$7,200/year
More expensive
QALY Difference
+0.40 QALYs
Better outcomes
Dominance
No dominance
Finerenone Outcomes
for Chronic Kidney Disease Due To Diabetes Mellitus Type 2
Efficacy Outcomes
Overall Effectiveness
+88%
Response Rate
+75%
Common Side Effects
Hyperkalemia
+15%
Hypotension
+4%
Active Clinical Trials
2 active trials recruiting for Finerenone in Chronic Kidney Disease Due To Diabetes Mellitus Type 2
Effect of Treatment With Finerenone on Cardio-Renal Target Organ Damage in Patients With Type 2 Diabetes.
NCT07026539RECRUITINGPHASE4
80 participants
INTERVENTIONAL
Aarhus N, Denmark
Started: Oct 23, 2024
Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial
NCT06094920ENROLLING BY INVITATIONPHASE4
10 participants
INTERVENTIONAL
Almelo, Netherlands
Started: Aug 5, 2024